| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/24/2013 | WO2013158814A1 Immediate release, abuse deterrent pharmaceutical compositions |
| 10/24/2013 | WO2013158810A1 Immediate release pharmaceutical compositions with abuse deterrent properties |
| 10/24/2013 | WO2013158318A1 Formulations and methods for treatment of acne and inflammatory skin conditions |
| 10/24/2013 | WO2013158317A1 Formulations and methods for treatment of inflammatory skin diseases |
| 10/24/2013 | WO2013157648A1 Pharmaceutical composition |
| 10/24/2013 | WO2013156957A1 Compounds for the prevention or treatment of infections with viruses of the flaviviridae family |
| 10/24/2013 | WO2013156035A1 Orally available pharmaceutical formulation suitable for improved management of movement disorders |
| 10/24/2013 | WO2013061309A3 New a-prp medical device & tissue engineering composition, manufacturing machines and process |
| 10/24/2013 | US20130281876 Therapies for improving pulmonary function |
| 10/24/2013 | US20130281547 Purified Amphiphilic Peptide Compositions and Uses Thereof |
| 10/24/2013 | US20130281541 Use in brain degenerative diseases |
| 10/24/2013 | US20130281539 Highly Selective 5-HT(2C) Receptor Agonists That Show Anti-Psychotic Effects with Antagonist Activity at the 5-HT(2B) Receptor |
| 10/24/2013 | US20130281532 Compositions for topical treatment of microbial infections |
| 10/24/2013 | US20130281523 Low dose cannabinoid medicaments |
| 10/24/2013 | US20130281522 Methods for alzheimer's disease treatment and cognitive enhancement |
| 10/24/2013 | US20130281513 siRNA FOR INHIBITION OF Hif1alpha EXPRESSION AND ANTICANCER COMPOSITION CONTAINING THE SAME |
| 10/24/2013 | US20130281509 Antisense modulation of fibroblast growth factor receptor 4 expression |
| 10/24/2013 | US20130281501 Topical localized isoxazoline formulation |
| 10/24/2013 | US20130281498 Aminothiazole modulators of beta-3-adrenoreceptor |
| 10/24/2013 | US20130281497 Macrocyclic compounds and methods of treatment |
| 10/24/2013 | US20130281463 Diaza-spiro[5.5]undecanes useful as orexin receptor antagonists |
| 10/24/2013 | US20130281450 Isoindolone derivatives |
| 10/24/2013 | US20130281449 Oxazine Derivatives and their Use in the Treatment of Neurological Disorders |
| 10/24/2013 | US20130281447 Jnk inhibitors for the treatment of endometriosis |
| 10/24/2013 | US20130281446 Xinafoate salt of n4-(2,2-difluoro-4h-benzo[1,4]oxazin-3-one)-6-yl]-5-fluoro-n2-[3-(methylaminocarbonylmethyleneoxy)phenyl]2,4-pyrimidinediamine |
| 10/24/2013 | US20130281445 Compounds useful as inhibitors of choline kinase |
| 10/24/2013 | US20130281433 Therapeutic compounds |
| 10/24/2013 | US20130281432 Pyridinones/pyrazinones, method of making, and method of use thereof |
| 10/24/2013 | US20130281430 Amino-Indolyl-Substituted Imidazolyl-Pyrimidines and Their Use as Medicaments |
| 10/24/2013 | US20130281429 2,4-diamino-pyrimidines as aurora inhibitors |
| 10/24/2013 | US20130281414 Thiazolidinedione analogues |
| 10/24/2013 | US20130281410 Methods for the treatment of psychiatric disorders |
| 10/24/2013 | US20130281403 Compounds and compositions for the treatment of parasitic diseases |
| 10/24/2013 | US20130281402 Hdac inhibiting derivatives of camptothecin |
| 10/24/2013 | US20130281401 Combination therapy for the treatment of depression and other non-infectious diseases |
| 10/24/2013 | US20130281399 Treatment of diseases by epigenetic regulation |
| 10/24/2013 | US20130281398 Treatment of diseases by epigenetic regulation |
| 10/24/2013 | US20130281397 Treatment of diseases by epigenetic regulation |
| 10/24/2013 | US20130281396 Treatment of diseases by epigenetic regulation |
| 10/24/2013 | US20130281392 Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof |
| 10/24/2013 | US20130281389 Novel drug targets to overcome de novo drug-resistance in multiple myeloma |
| 10/24/2013 | US20130281388 Opioid agonist antagonist combinations |
| 10/24/2013 | US20130281387 Chemosensory Receptor Ligand-Based Therapies |
| 10/24/2013 | US20130281373 Combination therapy |
| 10/24/2013 | US20130281366 Heterocyclic compounds suitable for the treatment of dyslipidemia |
| 10/24/2013 | US20130281365 Fused aromatic ptp-1b inhibitors |
| 10/24/2013 | US20130281360 Broad spectrum antibiotic arylomycin analogs |
| 10/24/2013 | US20130281359 New bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
| 10/24/2013 | US20130281358 Peptide |
| 10/24/2013 | US20130281357 Anti-angiogenic agent and methods of using such agent |
| 10/24/2013 | US20130280760 High purity lipopetides |
| 10/24/2013 | US20130280336 Nanoparticle comprising rapamycin and albumin as anticancer agent |
| 10/24/2013 | US20130280304 Method of administration of active agents to non-human mammals |
| 10/24/2013 | US20130280278 Anti-vegfr-3 antibody compositions |
| 10/24/2013 | US20130280277 Notch1 receptor binding agents and methods of use thereof |
| 10/24/2013 | US20130280276 Antibody targeting osteoclast-related protein siglec-15 |
| 10/24/2013 | US20130280264 Total and Phosphorylated IL-1 Receptor-Associated Kinase-1 and IL-1 Receptor-Associated Kinase-4 as a Biomarker for Cancer Progression and Chemotherapy Resistance |
| 10/24/2013 | US20130280258 Prognostic, diagnostic, and cancer therapeutic uses of fanci and fanci modulating agents |
| 10/24/2013 | US20130280253 Il-1 binding proteins |
| 10/24/2013 | US20130280245 3-Aryl-6-aryl-[1,2,4]triazolo[4,3-alpha]pyridines as Inhibitors of Cell Proliferation and the Use Thereof |
| 10/24/2013 | US20130280243 COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR |
| 10/24/2013 | US20130280233 Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells |
| 10/24/2013 | US20130280231 Composition for preventing or treating obesity |
| 10/24/2013 | US20130280223 Functionalized tissue matrices |
| 10/24/2013 | US20130280220 Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| 10/24/2013 | US20130280214 Polycyclic heterocycle derivatives and methods of use thereof for the treatment of viral diseases |
| 10/24/2013 | US20130280213 Estriol therapy for multiple sclerosis and other autoimmune diseases |
| 10/24/2013 | US20130280212 Inhibitors of cytochrome p450 |
| 10/24/2013 | US20130280211 Hepatitis C Virus Inhibitors |
| 10/24/2013 | US20130280210 Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase |
| 10/24/2013 | US20130280207 Compositions and methods for reducing the risk of spontaneous abortion in a human female |
| 10/24/2013 | US20130280163 Antibodies and molecules derived therefrom that bind to STEAP-1 proteins |
| 10/24/2013 | US20130280162 uPAR-ANTAGONISTS AND USES THEREOF |
| 10/23/2013 | EP2653158A1 Therapeutic agent for blood-brain barrier disruption syndrome |
| 10/23/2013 | EP2651975A1 Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof |
| 10/23/2013 | EP2651864A1 Methods and devices for using isoperillyl alcohol |
| 10/23/2013 | EP2651427A1 Novel therapeutic strategies for improving an anticancer treatment |
| 10/23/2013 | EP2651249A2 Whey protein composition with a reduced astringency |
| 10/23/2013 | CN103369975A Whey protein composition with a reduced astringency |
| 10/23/2013 | CN103361424A MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors |
| 10/23/2013 | CN103361336A Animal model with male reproductive disorders, as well as preparation method and application thereof |
| 10/23/2013 | CN103360403A Compound having cytotoxicity, composition, and preparation method and use thereof |
| 10/23/2013 | CN103357025A Application of BRSK2 in preparation of medicines for inhibiting pancreatic cancer |
| 10/23/2013 | CN103357018A Nerve injury-resistant effect of cyclooxygenase (COX) inhibitor enhanced rho kinase inhibitor |
| 10/23/2013 | CN103357017A Application of met-RANTES in preparing medicine used for treating inherited retinal degeneration |
| 10/23/2013 | CN103357016A Pharmaceutical composition for treating drug-resistant tuberculosis |
| 10/23/2013 | CN103357015A Local preparation for removing verruca and nail diseases and taking care of nails |
| 10/23/2013 | CN103357014A Biofilm treatment |
| 10/23/2013 | CN103357013A Composition for enhancing bioavailability of taxane medicament |
| 10/23/2013 | CN103357012A Taxane self-emulsifying or self-microemulsifying drug transfer system and preparation method thereof |
| 10/23/2013 | CN103356996A Treatment of acute coronary syndrome with GLP-1 |
| 10/23/2013 | CN103356510A Methods for producing drug-containing bioabsorbable fibers |
| 10/23/2013 | CN103356489A Proton pump inhibitor enteric coated pellet and preparation and preparation method thereof |
| 10/23/2013 | CN103355668A Nutritional support to prevent or moderate bone marrow paralysis or neutropenia during anti-cancer treatment |
| 10/23/2013 | CN102585258B Gelatin embolism microsphere and preparation method and application thereof |
| 10/23/2013 | CN102233132B Application of VEGF acceptor fusion proteins in preparation of drugs for inhibiting growth of ocular surface neovascularization |
| 10/23/2013 | CN101985044B Taste-masking medicinal coating composition |
| 10/23/2013 | CN101657194B Pharmaceutical compositions comprising trigonelline and 4-hydroxyisoleucine and process thereof |
| 10/22/2013 | US8563538 Preventing and/or treating cardiovascular disease and/or associated heart failure |
| 10/22/2013 | US8563236 Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance |